Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-04-29

FDA Approved: TRI-LINYAH — Supplemental Application (Northstar Rx LLC)

View source ↗

Summary

FDA approved a supplemental application for TRI-LINYAH (norgestimate and ethinyl estradiol) submitted by Northstar Rx LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • TRI-LINYAH (NORGESTIMATE AND ETHINYL ESTRADIOL)

Snippet

SUPPL AP for TRI-LINYAH (NORGESTIMATE AND ETHINYL ESTRADIOL)